Mesoblast Limited (MESO)

Revenue by Segment

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Development and Commercialization of Its Allogeneic Cellular Medicines Platform	120.25M	17.20M	5.90M	7.50M	10.21M
Total	120.25M	17.20M	5.90M	7.50M	10.21M

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 13, 2026

Data Sources Report a data error